Literature DB >> 14637280

Remnant-like particles from subjects who died of coronary artery disease suppress NO synthase activity and attenuate endothelium-dependent vasorelaxation.

Naoki Ohara1, Sanae Takeichi, Yukiko Naito, Yasuhiro Nakajima, Nobuhiro Yukawa, Takamitsu Nakano, Katsuyuki Nakajima.   

Abstract

BACKGROUND: Plasma levels of remnant-like particles (RLP) is one of the predictive markers for coronary artery disease (CAD), and the inhibition by RLP of endothelium-dependent vasorelaxation has been reported. We attempted to clarify whether or not RLP, which inhibits endothelium-dependent vasorelaxation, affects nitric oxide (NO) production and NO synthase (eNOS) levels in cultured endothelial cells.
METHODS: RLP were obtained from postmortem blood of subjects who died of CAD. Modification by RLP of acetylcholine-induced relaxation of rabbit aorta, and changes in NO production and (eNOS) in cultured bovine endothelial cells were examined.
RESULTS: RLP at 750 and 1500 microg triglyceride/ml inhibited vasorelaxation, and at 5-160 microg triglyceride/ml, concentration-dependently inhibited NO production. However, (eNOS) did not decrease after incubation with RLP.
CONCLUSION: Postmortem RLP from subjects who died of CAD do not change the amount of (eNOS), but rather, inhibits its activity and attenuates endothelium-dependent vasorelaxation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637280     DOI: 10.1016/j.cccn.2003.08.014

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

1.  Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.

Authors:  Masatoki Yoshida; Kazufumi Nakamura; Toru Miyoshi; Masashi Yoshida; Megumi Kondo; Kaoru Akazawa; Tomonari Kimura; Hiroaki Ohtsuka; Yuko Ohno; Daiji Miura; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2020-09-26       Impact factor: 9.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.